The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
Akums Drugs will undertake this development and commercialization in India
e brings over 27+ years of rich pharmaceutical experience
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
Subscribe To Our Newsletter & Stay Updated
